Acceleron Pharma Inc (XLRN)

41.15
0.61 1.50
NASDAQ
Prev Close 40.54
Open 40.31
Day Low/High 39.99 / 41.30
52 Wk Low/High 32.53 / 59.59
Volume 120.22K
Exchange NASDAQ
Shares Outstanding 52.68B
Market Cap 2.19B
Div & Yield N.A. (N.A)

Latest News

Acceleron Discontinues Development Of Phase 1 Molecule ACE-2494

Acceleron Discontinues Development Of Phase 1 Molecule ACE-2494

Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced it is discontinuing development of ACE-2494, a systemic...

Acceleron Receives FDA Orphan Drug Designation For ACE-083 In Charcot-Marie-Tooth Disease

Acceleron Receives FDA Orphan Drug Designation For ACE-083 In Charcot-Marie-Tooth Disease

Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced that the United States Food and Drug Administration (FDA)...

Acceleron Reports Fourth Quarter And Full Year 2018 Operating And Financial Results

Acceleron Reports Fourth Quarter And Full Year 2018 Operating And Financial Results

Acceleron Pharma Inc. (Nasdaq: XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, today provided a corporate update and reported financial results for the...

Acceleron Pharma Is Ready to Rally Ahead of Earnings

Acceleron Pharma Is Ready to Rally Ahead of Earnings

Here's how to trade XLRN stock right now.

Acceleron To Webcast Fourth Quarter And Full Year 2018 Operating And Financial Results On February 27, 2019

Acceleron To Webcast Fourth Quarter And Full Year 2018 Operating And Financial Results On February 27, 2019

Acceleron Pharma Inc. (Nasdaq:XLRN) today announced it will host a webcast and conference call on Wednesday, February 27, 2019 at 5:00 p.

Acceleron To Present At Two Upcoming Healthcare Investor Conferences

Acceleron To Present At Two Upcoming Healthcare Investor Conferences

Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics intended to treat serious and rare diseases, today announced that senior management will present at two upcoming...

Acceleron Announces Pricing Of Public Offering Of Common Stock

Acceleron Announces Pricing Of Public Offering Of Common Stock

Acceleron Pharma Inc. (Nasdaq: XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics intended to treat serious and rare hematologic, neuromuscular, and pulmonary diseases, today announced that it...

Acceleron Announces Proposed Public Offering Of Common Stock

Acceleron Announces Proposed Public Offering Of Common Stock

Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare hematologic, neuromuscular, and pulmonary diseases, today announced that it intends to...

Acceleron Announces Publication Of Luspatercept Phase 2 Beta-Thalassemia Study Results In Blood

Acceleron Announces Publication Of Luspatercept Phase 2 Beta-Thalassemia Study Results In Blood

Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced that the journal Blood has published results from the Phase 2 study of...

Acceleron To Webcast Presentation At The 37th Annual J.P. Morgan Healthcare Conference

Acceleron To Webcast Presentation At The 37th Annual J.P. Morgan Healthcare Conference

Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced that Habib Dable, President and Chief Executive Officer, will present an...

Acceleron Announces Luspatercept Phase 3 MEDALIST And BELIEVE Presentations Selected For "Best Of ASH" By The American Society Of Hematology

Acceleron Announces Luspatercept Phase 3 MEDALIST And BELIEVE Presentations Selected For "Best Of ASH" By The American Society Of Hematology

Acceleron Pharma Inc. (Nasdaq:XLRN) today announced that the presentations of the MEDALIST and BELIEVE Phase 3 trial results of luspatercept in patients with lower-risk myelodysplastic syndromes (MDS) and beta-thalassemia associated anemias, respectively,...

Celgene Corporation And Acceleron Pharma Announce Results Of The Phase 3 BELIEVE Trial Evaluating Luspatercept In Adult Patients With Beta-Thalassemia At ASH 2018

Celgene Corporation And Acceleron Pharma Announce Results Of The Phase 3 BELIEVE Trial Evaluating Luspatercept In Adult Patients With Beta-Thalassemia At ASH 2018

Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced results from a pivotal, phase 3 trial (BELIEVE) evaluating the safety and efficacy of luspatercept for the treatment of adults with beta-thalassemia-associated...

Acceleron Receives FDA Fast Track Designation For ACE-083 In Charcot-Marie-Tooth Disease

Acceleron Receives FDA Fast Track Designation For ACE-083 In Charcot-Marie-Tooth Disease

Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced that the United States Food and Drug Administration (FDA) has granted...

Acceleron To Host Conference Call And Webcast To Review MEDALIST And BELIEVE Phase 3 Trial Presentations Of Luspatercept At The 60th American Society Of Hematology Annual Meeting

Acceleron To Host Conference Call And Webcast To Review MEDALIST And BELIEVE Phase 3 Trial Presentations Of Luspatercept At The 60th American Society Of Hematology Annual Meeting

Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced it will host a conference call and live audio webcast on Monday,...

Acceleron To Participate In Two Upcoming Healthcare Investor Conferences

Acceleron To Participate In Two Upcoming Healthcare Investor Conferences

Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced that senior management will participate in two upcoming healthcare...

Acceleron Announces Preclinical Presentations On Sotatercept In Pulmonary Arterial Hypertension At The 2018 American Heart Association Scientific Session

Acceleron Announces Preclinical Presentations On Sotatercept In Pulmonary Arterial Hypertension At The 2018 American Heart Association Scientific Session

Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced plans to deliver three preclinical presentations on sotatercept in...

Acceleron Announces That Phase 3 Results From The MEDALIST And BELIEVE Trials Of Luspatercept Will Be Presented At The 60th American Society Of Hematology Annual Meeting

Acceleron Announces That Phase 3 Results From The MEDALIST And BELIEVE Trials Of Luspatercept Will Be Presented At The 60th American Society Of Hematology Annual Meeting

Acceleron Pharma Inc. (Nasdaq:XLRN) today announced that results from the MEDALIST and BELIEVE Phase 3 trials of luspatercept in patients with low-to-intermediate risk myelodysplastic syndromes (MDS) and transfusion-dependent beta-thalassemia,...

Acceleron Reports Third Quarter 2018 Operating And Financial Results

Acceleron Reports Third Quarter 2018 Operating And Financial Results

Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today provided a corporate update and reported financial results for the third quarter...

First Week Of XLRN May 2019 Options Trading

First Week Of XLRN May 2019 Options Trading

Investors in Acceleron Pharma, Inc. saw new options become available this week, for the May 2019 expiration.

Acceleron To Webcast Third Quarter 2018 Operating And Financial Results On October 30, 2018

Acceleron To Webcast Third Quarter 2018 Operating And Financial Results On October 30, 2018

Acceleron Pharma Inc. (Nasdaq:XLRN) today announced it will host a webcast and conference call on Tuesday, October 30, 2018 at 4:30 p.

Acceleron To Host Pulmonary Arterial Hypertension Research And Development Deep Dive Event On November 16, 2018 In New York City

Acceleron To Host Pulmonary Arterial Hypertension Research And Development Deep Dive Event On November 16, 2018 In New York City

Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced it will webcast a live presentation from its Pulmonary Arterial...

Acceleron Announces Presentations On ACE-083 At The 23rd International Annual Congress Of The World Muscle Society

Acceleron Announces Presentations On ACE-083 At The 23rd International Annual Congress Of The World Muscle Society

Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced plans to deliver poster presentations on ACE-083 from Part 1 of each its...

Acceleron To Participate In Three Upcoming Healthcare Investor Conferences

Acceleron To Participate In Three Upcoming Healthcare Investor Conferences

Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced that senior management will participate in three upcoming healthcare...

Acceleron Reports Second Quarter 2018 Operating And Financial Results

Acceleron Reports Second Quarter 2018 Operating And Financial Results

Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today provided a corporate update and reported financial results for the second quarter...

Notable Tuesday Option Activity: XLRN, ARAY, X

Notable Tuesday Option Activity: XLRN, ARAY, X

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Acceleron Pharma, Inc. , where a total volume of 3,811 contracts has been traded thus far today, a contract volume which is representative of approximately 381,100 underlying shares (given that every 1 contract represents 100 underlying shares).

Acceleron To Webcast Second Quarter 2018 Operating And Financial Results On August 2, 2018

Acceleron To Webcast Second Quarter 2018 Operating And Financial Results On August 2, 2018

Acceleron Pharma Inc. (NASDAQ:XLRN) today announced it will host a webcast and conference call on Thursday, August 2, 2018 at 5:00 p.

Acceleron Announces Preliminary Results From Part 1 Of The ACE-083 Phase 2 Trial In Patients With Charcot-Marie-Tooth Disease At The 2018 Annual Meeting Of The Peripheral Nerve Society

Acceleron Announces Preliminary Results From Part 1 Of The ACE-083 Phase 2 Trial In Patients With Charcot-Marie-Tooth Disease At The 2018 Annual Meeting Of The Peripheral Nerve Society

Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced positive preliminary results from Part 1 of the Phase 2 clinical trial...

Acceleron Receives FDA Orphan Drug Designation For ACE-083 In Facioscapulohumeral Muscular Dystrophy

Acceleron Receives FDA Orphan Drug Designation For ACE-083 In Facioscapulohumeral Muscular Dystrophy

Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced that the United States Food and Drug Administration (FDA) has granted...